Conference Details - Overview

Back to Conferences

Continuing Education Information

Physicians: Physicians' Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™

Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Oncology Best Practices: Targeted Therapies for Breast Cancer

The Ritz Restaurant and Garden
Newport Beach, CA
July 29, 2009

Conference Overview

Summary and Purpose

Oncology CME-Certified Meeting

The Oncology Best Practices: Targeted Therapies for Breast Cancer meeting is designed to update community oncologists on the latest data on novel biologic agents for both early-stage and advanced/metastatic breast cancer. The format will consist of didactic lectures coupled with extended case-based discussions that will address current and new treatment strategies.

Additional CME Accreditation and Credit Designation Information

Registered Nurse: The California Board of Registered Nursing accepts AMA PRA Category 1 CreditsTM toward license renewal. On the BRN license renewal form, report the number of hours you attended (up to XX hours of credit) and fill in “CME Category 1” for the provider number.

California AB 1195:  This activity complies with California Assembly Bill 1195, signed November 2005, requiring continuing medical education courses with patient care components to include curricula in the subject of cultural and linguistic competency.  The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend.

Learning Objectives

At the conclusion of this meeting, you should be able to:

  • Assess results from adjuvant trials incorporating HER2-targeted agents into the treatment of HER2+ early-stage breast cancer
  • Discuss antibodies and small-molecule tyrosine kinase inhibitors targeting the HER2 receptor and their integration into current treatment algorithms
  • Compare and contrast first-line treatment options, including combinations of HER2-targeted agents with chemotherapy or endocrine therapy as well as investigational combinations of biologic agents, in HER2+ metastatic breast cancer
  • Review novel classes of targeted biologic agents currently under investigation in the treatment of metastatic breast cancer
  • Apply new data on the combination of cytotoxic agents with antiangiogenic agents
  • Refer appropriate patients to promising clinical trials

Educational Grants

An educational grant for this activity was provided by:


  1. Genentech BioOncology